Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Experimental Characterization of Polymer Surfaces Subject to Corona Discharges in Controlled Atmospheres.

Leon-Garzon AR, Dotelli G, Tommasini M, Bianchi CL, Pirola C, Villa A, Lucotti A, Sacchi B, Barbieri L.

Polymers (Basel). 2019 Oct 10;11(10). pii: E1646. doi: 10.3390/polym11101646.

2.

Nonalcoholic steatohepatitis pharmacotherapy and predictors of response: dual role of aminotransferases as biosensors of metabolism and biomarkers of histological improvement.

Sookoian S, Pirola CJ.

Hepatobiliary Surg Nutr. 2019 Aug;8(4):381-385. doi: 10.21037/hbsn.2019.02.04. No abstract available.

3.

Repurposing drugs to target nonalcoholic steatohepatitis.

Sookoian S, Pirola CJ.

World J Gastroenterol. 2019 Apr 21;25(15):1783-1796. doi: 10.3748/wjg.v25.i15.1783. Review.

4.

Photocatalytic porcelain grés large slabs digitally coated with AgNPs-TiO2.

Bianchi CL, Cerrato G, Pirola C, Galli F, Capucci V.

Environ Sci Pollut Res Int. 2019 Apr 25. doi: 10.1007/s11356-019-05218-7. [Epub ahead of print]

PMID:
31020536
5.

Genetics of Nonalcoholic Fatty Liver Disease: From Pathogenesis to Therapeutics.

Sookoian S, Pirola CJ.

Semin Liver Dis. 2019 May;39(2):124-140. doi: 10.1055/s-0039-1679920. Epub 2019 Mar 25.

PMID:
30912099
6.

Review article: shared disease mechanisms between non-alcoholic fatty liver disease and metabolic syndrome - translating knowledge from systems biology to the bedside.

Sookoian S, Pirola CJ.

Aliment Pharmacol Ther. 2019 Mar;49(5):516-527. doi: 10.1111/apt.15163. Epub 2019 Feb 4. Review.

PMID:
30714632
7.

Tackling the complexity of nonalcoholic steatohepatitis treatment: challenges and opportunities based on systems biology and machine learning approaches.

Pirola CJ, Sookoian S.

Hepatobiliary Surg Nutr. 2018 Dec;7(6):495-498. doi: 10.21037/hbsn.2018.09.06. No abstract available.

8.

Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease.

Pirola CJ, Garaycoechea M, Flichman D, Arrese M, San Martino J, Gazzi C, Castaño GO, Sookoian S.

J Lipid Res. 2019 Jan;60(1):176-185. doi: 10.1194/jlr.P089953. Epub 2018 Oct 15.

PMID:
30323112
9.

Micro-TiO2 coated glass surfaces safely abate drugs in surface water.

Cerrato G, Bianchi CL, Galli F, Pirola C, Morandi S, Capucci V.

J Hazard Mater. 2019 Feb 5;363:328-334. doi: 10.1016/j.jhazmat.2018.09.057. Epub 2018 Sep 25.

PMID:
30321837
10.

Angiotensin II requires an intact cardiac thyrotropin-releasing hormone (TRH) system to induce cardiac hypertrophy in mouse.

Peres Diaz LS, Schuman ML, Aisicovich M, Toblli JE, Pirola CJ, Landa MS, García SI.

J Mol Cell Cardiol. 2018 Nov;124:1-11. doi: 10.1016/j.yjmcc.2018.09.009. Epub 2018 Sep 27.

PMID:
30267750
11.

Editorial: surviving your genes-the role of PNPLA3 variation in end-stage liver disease.

Pirola CJ, Sookoian S.

Aliment Pharmacol Ther. 2018 Oct;48(7):773-775. doi: 10.1111/apt.14901. No abstract available.

PMID:
30246305
12.

A Rare Nonsense Mutation in the Glucokinase Regulator Gene Is Associated With a Rapidly Progressive Clinical Form of Nonalcoholic Steatohepatitis.

Pirola CJ, Flichman D, Dopazo H, Fernández Gianotti T, San Martino J, Rohr C, Garaycoechea M, Gazzi C, Castaño GO, Sookoian S.

Hepatol Commun. 2018 Sep 5;2(9):1030-1036. doi: 10.1002/hep4.1235. eCollection 2018 Sep.

13.
14.

Ultrasound-assisted impregnation for high temperature Fischer-Tropsch catalysts.

Louyot P, Neagoe C, Galli F, Pirola C, Patience GS, Boffito DC.

Ultrason Sonochem. 2018 Nov;48:523-531. doi: 10.1016/j.ultsonch.2018.06.017. Epub 2018 Jun 23.

PMID:
30080581
15.

Metastasis-associated lung adenocarcinoma transcript 1 as a common molecular driver in the pathogenesis of nonalcoholic steatohepatitis and chronic immune-mediated liver damage.

Sookoian S, Flichman D, Garaycoechea ME, San Martino J, Castaño GO, Pirola CJ.

Hepatol Commun. 2018 Apr 16;2(6):654-665. doi: 10.1002/hep4.1184. eCollection 2018 Jun.

16.

Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity.

Pirola CJ, Sookoian S.

World J Gastroenterol. 2018 Apr 21;24(15):1601-1615. doi: 10.3748/wjg.v24.i15.1601. Review.

17.

Production and application of O2 enriched air produced by fresh and salt water desorption in chemical plants.

Galli F, Previtali D, Bozzano G, Bianchi CL, Manenti F, Pirola C.

J Environ Manage. 2018 Jul 1;217:621-628. doi: 10.1016/j.jenvman.2018.03.133. Epub 2018 Apr 9.

PMID:
29649734
18.

Lack of evidence supporting a role of TMC4-rs641738 missense variant-MBOAT7- intergenic downstream variant-in the Susceptibility to Nonalcoholic Fatty Liver Disease.

Sookoian S, Flichman D, Garaycoechea ME, Gazzi C, Martino JS, Castaño GO, Pirola CJ.

Sci Rep. 2018 Mar 23;8(1):5097. doi: 10.1038/s41598-018-23453-9.

19.

Comparison of Branched and Linear Perfluoropolyether Chains Functionalization on Hydrophobic, Morphological and Conductive Properties of Multi-Walled Carbon Nanotubes.

Sansotera M, Talaeemashhadi S, Gambarotti C, Pirola C, Longhi M, Ortenzi MA, Navarrini W, Bianchi CL.

Nanomaterials (Basel). 2018 Mar 19;8(3). pii: E176. doi: 10.3390/nano8030176.

20.

Nonalcoholic Fatty Liver Disease Progresses into Severe NASH when Physiological Mechanisms of Tissue Homeostasis Collapse.

Sookoian S, Pirola CJ.

Ann Hepatol. 2018 Mar 1;17(2):182-186. doi: 10.5604/01.3001.0010.8631.

21.

The nonalcoholic steatohepatitis metabotype: Imbalance of circulating amino acids and transamination reactions reflect impaired mitochondrial function.

Sookoian S, Pirola CJ.

Hepatology. 2018 Mar;67(3):1177-1178. doi: 10.1002/hep.29705. Epub 2018 Jan 30. No abstract available.

PMID:
29205411
22.

Simultaneous photodegradation of VOC mixture by TiO2 powders.

Stucchi M, Galli F, Bianchi CL, Pirola C, Boffito DC, Biasioli F, Capucci V.

Chemosphere. 2018 Feb;193:198-206. doi: 10.1016/j.chemosphere.2017.11.003. Epub 2017 Nov 5.

PMID:
29131978
23.

Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease.

Sookoian S, Pirola CJ.

Aliment Pharmacol Ther. 2018 Jan;47(1):16-25. doi: 10.1111/apt.14401. Epub 2017 Oct 30. Review.

24.

Serotonin-transporter promoter polymorphism modulates the ability to control food intake: Effect on total weight loss.

Bonnet G, Gómez-Abellán P, Vera B, Sánchez-Romera JF, Hernández-Martínez AM, Sookoian S, Pirola CJ, Garaulet M.

Mol Nutr Food Res. 2017 Nov;61(11). doi: 10.1002/mnfr.201700494. Epub 2017 Sep 1.

PMID:
28766852
25.

Letter: Mendelian randomisation to investigate moderate alcohol consumption in nonalcoholic fatty liver disease; modest effects need large numbers-authors' reply.

Sookoian S, Pirola CJ.

Aliment Pharmacol Ther. 2017 Aug;46(4):469-470. doi: 10.1111/apt.14182. No abstract available.

26.
27.

The natural history of nonalcoholic fatty liver disease: mortality rates and liver enzymes.

Pirola CJ, Sookoian S.

Hepatobiliary Surg Nutr. 2017 Apr;6(2):130-134. doi: 10.21037/hbsn.2017.03.02. No abstract available.

28.

Cell-free DNA methylation as liquid biopsy for the assessment of fibrosis in patients with nonalcoholic steatohepatitis: a gap between innovation and implementation.

Sookoian S, Pirola CJ.

Hepatobiliary Surg Nutr. 2017 Apr;6(2):117-121. doi: 10.21037/hbsn.2017.01.07. No abstract available.

29.
30.

Micro-sized TiO2 as photoactive catalyst coated on industrial porcelain grès tiles to photodegrade drugs in water.

Bianchi CL, Sacchi B, Capelli S, Pirola C, Cerrato G, Morandi S, Capucci V.

Environ Sci Pollut Res Int. 2018 Jul;25(21):20348-20353. doi: 10.1007/s11356-017-9066-6. Epub 2017 Apr 27.

PMID:
28452026
31.

Genetic predisposition in nonalcoholic fatty liver disease.

Sookoian S, Pirola CJ.

Clin Mol Hepatol. 2017 Mar;23(1):1-12. doi: 10.3350/cmh.2016.0109. Epub 2017 Mar 9. Review.

32.

Genetic variation in long noncoding RNAs and the risk of nonalcoholic fatty liver disease.

Sookoian S, Rohr C, Salatino A, Dopazo H, Fernandez Gianotti T, Castaño GO, Pirola CJ.

Oncotarget. 2017 Apr 4;8(14):22917-22926. doi: 10.18632/oncotarget.15286.

33.

Mendelian randomisation suggests no beneficial effect of moderate alcohol consumption on the severity of nonalcoholic fatty liver disease.

Sookoian S, Flichman D, Castaño GO, Pirola CJ.

Aliment Pharmacol Ther. 2016 Dec;44(11-12):1224-1234. doi: 10.1111/apt.13828. Epub 2016 Oct 24.

34.

Fe-based heterogeneous catalysts for the Fischer-Tropsch reaction: Sonochemical synthesis and bench-scale experimental tests.

Comazzi A, Pirola C, Longhi M, Bianchi CL, Suslick KS.

Ultrason Sonochem. 2017 Jan;34:774-780. doi: 10.1016/j.ultsonch.2016.07.012. Epub 2016 Jul 19.

PMID:
27773304
35.

Aspirin and paracetamol removal using a commercial micro-sized TiO2 catalyst in deionized and tap water.

Bianchi CL, Sacchi B, Pirola C, Demartin F, Cerrato G, Morandi S, Capucci V.

Environ Sci Pollut Res Int. 2017 May;24(14):12646-12654. doi: 10.1007/s11356-016-7781-z. Epub 2016 Oct 21.

PMID:
27770326
36.

Nonalcoholic fatty liver disease and metabolic syndrome: Shared genetic basis of pathogenesis.

Sookoian S, Pirola CJ.

Hepatology. 2016 Nov;64(5):1417-1420. doi: 10.1002/hep.28746. Epub 2016 Aug 24. No abstract available.

PMID:
27480050
37.

Mitochondrial genome architecture in non-alcoholic fatty liver disease.

Sookoian S, Flichman D, Scian R, Rohr C, Dopazo H, Gianotti TF, Martino JS, Castaño GO, Pirola CJ.

J Pathol. 2016 Dec;240(4):437-449. doi: 10.1002/path.4803. Epub 2016 Oct 18.

PMID:
27577682
38.

Nonalcoholic fatty liver disease: Biomarkers support decisions around pharmacological intervention.

Sookoian S, Pirola CJ.

Hepatology. 2017 Apr;65(4):1417-1419. doi: 10.1002/hep.28866. Epub 2016 Nov 28. No abstract available.

PMID:
27737511
39.

The Exact Mechanism by Which Hepatic Transmembrane 6 Superfamily Member 2 Modulates Triglyceride Metabolism Is Still Uncertain.

Sookoian S, Pirola CJ.

Gastroenterology. 2016 Nov;151(5):1033-1034. doi: 10.1053/j.gastro.2016.03.055. Epub 2016 Oct 1. No abstract available.

PMID:
27702630
40.

Nonalcoholic steatohepatitis is associated with a state of betaine-insufficiency.

Sookoian S, Puri P, Castaño GO, Scian R, Mirshahi F, Sanyal AJ, Pirola CJ.

Liver Int. 2017 Apr;37(4):611-619. doi: 10.1111/liv.13249. Epub 2016 Oct 4.

PMID:
27614103
41.

Investigation of analyte losses using microwave-assisted sample digestion and closed vessels with venting.

Amaral CDB, Fialho LL, Camargo FPR, Pirola C, Nóbrega JA.

Talanta. 2016 Nov 1;160:354-359. doi: 10.1016/j.talanta.2016.07.041. Epub 2016 Jul 22.

42.

The impact of hypertension on leukocyte telomere length: a systematic review and meta-analysis of human studies.

Tellechea ML, Pirola CJ.

J Hum Hypertens. 2017 Feb;31(2):99-105. doi: 10.1038/jhh.2016.45. Epub 2016 Jun 30. Review.

PMID:
27357526
44.

Elafibranor for the treatment of NAFLD: One pill, two molecular targets and multiple effects in a complex phenotype.

Sookoian S, Pirola CJ.

Ann Hepatol. 2016 Jul-Aug;15(4):604-9. No abstract available.

45.

Copper NPs decorated titania: A novel synthesis by high energy US with a study of the photocatalytic activity under visible light.

Stucchi M, Bianchi CL, Pirola C, Cerrato G, Morandi S, Argirusis C, Sourkouni G, Naldoni A, Capucci V.

Ultrason Sonochem. 2016 Jul;31:295-301. doi: 10.1016/j.ultsonch.2016.01.015. Epub 2016 Jan 15.

PMID:
26964952
46.

Heat Shock Protein 27 is down-regulated in Ballooned Hepatocytes of Patients with Nonalcoholic Steatohepatitis (NASH).

Sookoian S, Castaño GO, Scian R, San Martino J, Pirola CJ.

Sci Rep. 2016 Mar 3;6:22528. doi: 10.1038/srep22528.

47.

Heterogeneous Phase Microwave-Assisted Reactions under CO₂ or CO Pressure.

Calcio Gaudino E, Rinaldi L, Rotolo L, Carnaroglio D, Pirola C, Cravotto G.

Molecules. 2016 Feb 24;21(3):253. doi: 10.3390/molecules21030253. Review.

48.

Metabolite Signatures of Metabolic Risk Factors and their Longitudinal Changes.

Yin X, Subramanian S, Willinger CM, Chen G, Juhasz P, Courchesne P, Chen BH, Li X, Hwang SJ, Fox CS, O'Donnell CJ, Muntendam P, Fuster V, Bobeldijk-Pastorova I, Sookoian SC, Pirola CJ, Gordon N, Adourian A, Larson MG, Levy D.

J Clin Endocrinol Metab. 2016 Apr;101(4):1779-89. doi: 10.1210/jc.2015-2555. Epub 2016 Feb 23.

49.

The modulation of liver methylome in liver diseases.

Pirola CJ, Sookoian S.

J Hepatol. 2016 Apr;64(4):987-8. doi: 10.1016/j.jhep.2015.12.024. Epub 2016 Jan 18. No abstract available.

PMID:
26795830
50.

Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level.

Sookoian S, Castaño GO, Scian R, Fernández Gianotti T, Dopazo H, Rohr C, Gaj G, San Martino J, Sevic I, Flichman D, Pirola CJ.

Am J Clin Nutr. 2016 Feb;103(2):422-34. doi: 10.3945/ajcn.115.118695. Epub 2016 Jan 20.

PMID:
26791191

Supplemental Content

Loading ...
Support Center